Petronela Weisova

Petronela Weisova PhD is currently working as the Sn.Clinical Strategy/Sn.Clinical Science Lead at Valneva, specializing in Chickungunya vaccine clinical development. Petronela also played a crucial role in the market authorization of the COVID-19 vaccine VLA2001. With a background in neuroimmunology and neurodegeneration, Petronela has extensive experience in academic-industry collaborations, clinical project management, and pre-clinical research in Alzheimer's disease and tauopathies. Petronela's expertise also includes clinical diagnostics for avian influenza and molecular neuroscience.